MOSAIQ® Evaluate
Integrated plan management and dose review

A new paradigm of treatment planning management
MOSAIQ® Evaluate
Integrated plan management and dose review

MOSAIQ Evaluate delivers a truly integrated oncology management system, providing comprehensive treatment planning tools such as plan management and dose review directly within MOSAIQ. Multiple plan evaluation, approval and promotion can now be performed inside the patient chart, allowing clinicians to review the entire treatment plan on any MOSAIQ workstation. The combination of MOSAIQ with powerful treatment planning functions in a single software framework offers a multitude of efficiency gains and quality improvements for oncology practices. Radiation Oncologists no longer have to go to the dosimetrist’s office to review and approve plans, saving time and reducing treatment delays.

MOSAIQ Evaluate is not available for sale or distribution in all markets. Please contact your local Elekta representative for details.
Why MOSAIQ® Evaluate?

Provide the tools to help clinicians improve treatment quality with multiple RT plan, dose and DVH review within MOSAIQ

View an interactive display of the actual RT Plan and DRRs in MOSAIQ

Send the RT plan and reference images concurrently from virtually any Treatment Planning System (TPS) to MOSAIQ or in any sequence

Manage plans for different treatment modalities on any MOSAIQ workstation

Export, archive and restore plans, DICOM images and RT objects with MOSAIQ® Data Director
MOSAIQ® Evaluate supports the management of plans for different modalities and multi-modality images, photon, electron, brachytherapy and proton plans while powerful graphical displays and analytical tools help you to compare and quantify information. This helps clinicians compare plans from different systems, quantify and evaluate dose coverage trade-offs, to ensure the best possible course of treatment for each patient.

MOSAIQ Evaluate enables closer integration of treatment planning functions into the MOSAIQ clinical workflow while enabling the planning system access to all clinical treatment data, necessary for adaptive therapy, and ultimately evidence-based treatment.
With MOSAIQ Evaluate, users can:

- Display the treatment plan within the EMR
- View dose and beams on registered images
- Plan summation and subtraction
- Configure Multi-User approvals
- Review DVH Goal assessment
- View DVH Display
- Compare rival trial plans

MOSAIQ Plan Worklist identifies approved plans and triggers QA check

Approve plan and associated prescription

Treatment is initiated
Deliver more efficient patient care

With MOSAIQ Evaluate the planning system now has access to all clinical treatment data from MOSAIQ, enabling the clinician and planning staff to adapt the plan as changes occur in the treatment course, based on the wealth of clinical data available in the patient chart.

The Radiation Oncologist, Physicist, Dosimetrist and patients will realize the benefits of MOSAIQ Evaluate through streamlining planning activities inside the EMR, reducing patient wait times and delays and improving efficiency and productivity in the department.

- Streamline workflow
- Improve productivity
- Reduce delays to treatment

- Review and approve multiple plans on any MOSAIQ workstation – no need to go to planning room
- Simplify QA checks
- Assist clinical decision making

- Evaluate multiple plans from various treatment planning systems
- Manage plans for different treatment modalities
- Streamline Treatment Field creation
With MOSAIQ Evaluate, plan data is directly integrated into MOSAIQ, creating opportunities for data mining and retrospective queries on historical plan information.
A human care company, Elekta pioneers significant innovations and clinical solutions for treating cancer and brain disorders. Elekta provides intelligent and resource-efficient technologies that improve, prolong and save patient lives. We go beyond collaboration seeking long-term relationships built on trust with a shared vision, offering confidence to healthcare providers and their patients.